Close Menu

More articles about Diagnostics

The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples.

The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.

On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.

The deal provides whole-genome sequencing for patients with rare diseases or cancer and could make sequencing part of the standard of care for NHS England.

The new test increases the multiplexing of the sepsis panel from 26 targets to 43 targets, including seven additional resistance genes.

GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.

The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.

The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.

On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.

The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.

Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.

The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.

Contextual Genomics' recently launched assay screens for cell-free circulating tumor DNA in plasma to identify somatic genome alterations.

The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.

The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.

The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

The company said it anticipates $19.2 million in revenues for full-year 2019, which would miss the consensus Wall Street estimate of $19.4 million.

The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.

Though the firm's top-line figures fell just shy of analysts' estimates, its installed base of ePlex analyzers grew 49 percent year over year.

Pages

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.